Rocket Pharmaceuticals, Inc. (FWB:9IP1) Financings

Rocket Pharmaceuticals, Inc.

Financings

RaiseDate
Term loan credit facility with warrants
Tranche closed: US$35M raised · warrants to purchase shares of Rocket's common stock · LifeSci Capital +1
Dealers: LifeSci Capital, PJT
Buyers: Hercules Capital, Inc. (credit facility for up to $150 million; $35 million funded at closing)
Use of proceeds: Support the pivotal Phase 2 study of RP-A501 for Danon disease and advance the broader cardiovascular pipeline
Oct 6, 2026
Public offering of shares of common stock
Made bigger: US$165M · US$12.5 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), Cantor (co-lead), LifeSci Capital
Dec 11, 2024

Read by 6ix AI from the company's releases